RIGL - Rigel Pharmaceuticals, Inc.
NEXT EARNINGS:
Mar 3, 2026
(in 6 days)
EPS Est: $1.33
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.00
DETAILS
HIGH:
$42.00
LOW:
$38.00
MEDIAN:
$40.00
CONSENSUS:
$40.00
UPSIDE:
15.91%
Market Cap:
626.40M
Volume:
299,372
Avg Volume:
455,456
52 Week Range:
15.5-52.24
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.09
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
162
IPO Date:
2000-11-29
EPS (TTM):
0.99
P/E Ratio:
16.91
Revenue (TTM):
179.28M
Total Assets:
163.98M
Total Debt:
59.97M
Cash & Equiv:
56.75M
Rev Growth (5Y):
24.8%
EPS Growth (5Y):
-3.5%
FCF Growth (5Y):
N/A
ROCE:
26.1%
Debt/Equity:
18.24
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $1.46 | $0.93 | +57.0% | $69.5M | $68.4M | +1.5% |
| 2025-08-05 | $3.28 | $1.97 | +66.5% | $101.7M | $62.3M | +63.2% |
| 2025-05-06 | $0.63 | $0.14 | +350.0% | $53.3M | $48.3M | +10.4% |
| 2025-03-04 | $0.80 | $0.30 | +166.7% | $57.6M | $57.6M | 0.0% |
| 2024-11-07 | $0.70 | $0.06 | +1066.7% | $55.3M | $47.4M | +16.6% |
| 2024-08-06 | $-0.06 | $-0.37 | +83.8% | $36.8M | $33.4M | +10.2% |
| 2024-05-07 | $-0.50 | $-0.30 | -66.7% | $29.5M | $31.3M | -5.6% |
| 2024-03-05 | $0.04 | $0.02 | +100.0% | $35.8M | $34.1M | +5.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 179.28M | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M | 28.89M | 8.25M | 7.15M |
| Net Income | 17.48M | (25.09M) | (58.57M) | (17.91M) | (29.74M) | (66.55M) | (70.48M) | (77.99M) | (69.22M) | (51.46M) | (90.91M) | (89.03M) |
| EPS | 0.99 | -1.44 | -3.40 | -1.10 | -1.80 | -4.00 | -4.40 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 |
| Total Assets | 163.98M | 117.22M | 134.28M | 167.33M | 110.38M | 147.57M | 139.11M | 119.11M | 78.13M | 131.75M | 154.13M | 226.06M |
| Total Debt | 59.97M | 60.58M | 41.55M | 30.57M | 39.09M | 36.31M | 0 | 284,000 | 3.46M | 6.46M | 9.27M | 0 |
| Cash & Equivalents | 56.75M | 32.79M | 24.46M | 18.89M | 30.37M | 22.52M | 76.32M | 38.29M | 17.63M | 43.46M | 15.20M | 20.85M |
| Operating Cash Flow | 31.47M | (5.74M) | (73.76M) | 5.88M | (52.19M) | (41.51M) | (58.83M) | (77.56M) | (75.89M) | (23.41M) | (69.75M) | (86.06M) |
| Free Cash Flow | 31.07M | (20.74M) | (74.21M) | 5.25M | (53.45M) | (42.97M) | (59.93M) | (77.72M) | (76.69M) | (23.96M) | (70.17M) | (87.28M) |
| FCF per Share | 1.77 | -1.19 | -4.30 | 0.31 | -3.17 | -2.57 | -3.73 | -6.15 | -8.13 | -2.71 | -8.00 | -10.00 |
| Book Value | 3.29M | (28.64M) | (13.62M) | 30.37M | 34.03M | 53.81M | 109.88M | 100.65M | 55.03M | 91.38M | 128.25M | 208.25M |
| Cash & ST Investments | 77.32M | 56.93M | 58.21M | 124.97M | 57.33M | 98.08M | 128.54M | 115.75M | 74.77M | 126.28M | 143.16M | 211.97M |
| ROC Equity | 5.32 | N/A | N/A | -0.59 | -0.87 | -1.24 | -0.64 | -0.77 | -1.26 | -0.56 | -0.71 | -0.43 |